<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>
  • Using technology in tumor genomics to develop precision cancer therapeutics

    Investor Relations

Investor Relations

Welcome to Trovagene Investor Relations

Corporate Profile

We are a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging our proprietary Precision Cancer Monitoring® (PCM) technology and experience in tumor genomics.  Our broad intellectual property and proprietary technology allow us to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting patient response to cancer therapies.  We offer our PCM technology at our CLIA/CAP-accredited laboratory and plan to continue to vertically integrate our PCM technology with the development of precision cancer therapeutics.  We believe our ctDNA PCM technology and expertise in liquid biopsy testing provides a unique advantage for the development of precision cancer therapeutics.

Company Overview - October 19, 2017
Recent News
Oct 18, 2017

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced positive data from preclinical research demonstrating synergy of PCM-075, its oral, highly-selective...

Oct 9, 2017

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) granted an orphan drug designation to PCM-075 for the...

Sep 20, 2017

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the expansion and strengthening of its Board of Directors with the appointment of Athena Countouriotis, M.D.

More >

Stock Information
NASDAQTROV
Contact Investor Relations

Direct     [USA +1] 858-952-7593
E-mail    ir@trovagene.com

Contact

Events
September 12, 2017
5:05pm - 5:30pm EDT

Trovagene CEO, Bill Welch, will present an overview of the Company at the 19th Annual Rodman & Renshaw Gloabl Investment Conference on Tuesday, September 12th, at 5:05 pm EDT at the Lotte New York...

August 24, 2017
11:00am - 11:30am PDT

Bill Welch, CEO of Trovagene will be presenting an overview of the Company on Thursday, August 24th, at 11:00 am PDT.

June 15, 2017
12:00pm - 12:30pm PDT

Bill Welch, CEO of Trovagene, will be presenting at the Marcum 2017 MicroCap Conference on June 15, 2017 at 3:00 PM EDT at the Grand Hyatt Hotel in Julliard on the conference level. The...

3:34
3:34
Wistia video thumbnail - Susann-Berz Patient Video- Home Page

Thanks for reporting a problem. We'll attach technical data about this session to help us figure out the issue. Which of these best describes the problem?

Any other details or context?

Cancel
message